PROCEPT BioRobotics Azioni (NASDAQ: PRCT)

Ultime notizie per PROCEPT BioRobotics (NASDAQ:PRCT) Azioni

PROCEPT BIOROBOTICS CORP

PROCEPT BioRobotics

PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.

Long Ideas

News

Markets

Media

Trading Ideas

PRCT

Jim Cramer elogia Target per il suo rendimento del 3% e risultati finanziari eccellenti: ecco perché è un&#39;opportunità imperdibile!

Jim Cramer elogia questo titolo: &#34;Il rendimento del 3% è fantastico!&#34;

PROCEPT BioRobotics Corporation - Common Stock

PROCEPT BioRobotics Corp

B of A Securities analyst Craig Siegenthaler maintains T. Rowe Price Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TROW#NASDAQ">TROW</a>) with a Underperform and lowers the price target from $90 to $85.

Price Target

Analyst Ratings

TROW

B of A Securities Maintains Underperform on T. Rowe Price Group, Lowers Price Target to $85

B of A Securities analyst Michael Carrier maintains Invesco (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IVZ#NYSE">IVZ</a>) with a Neutral and lowers the price target from $19 to $18.

B of A Securities Maintains Neutral on Invesco, Lowers Price Target to $18

On CNBC's &#8220;<a href="https://www.cnbc.com/halftime/" target="_blank" rel="noopener">Halftime Report Final Trades</a>,&#8221; Rob Sechan of NewEdge Wealth said Gilead Sciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>) is one of the best-performing names in one of the best-performing sectors this year, still having a reasonable <a href="https://www.benzinga.com/quote/GILD/analyst-ratings" target="_blank" rel="noopener">valuation of 14 times.</a>
Supporting his view, JP Morgan analyst Chris Schott, on March 27, maintained Gilead Sciences with an Overweight rating and raised the price target from $120 to $130.
Bill Baruch of Blue Line Capital said Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) is ready to rally, with or without TikTok here. It had really good volume on its up days, he added.
Amazon.com has made a surprise, last-minute bid to acquire TikTok in its entirety, just days before the popular video app faces a U.S. ban if it does not sever ties with its Chinese parent company, The New York Times reported.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
Stephen Weiss of Short Hills Capital Partners named Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>).
WestPark Capital analyst Curtis Shauger initiated coverage on Alphabet on Tuesday with a Buy rating and a price target of $210.
Joseph M. Terranova of Virtus Investment Partners picked KLA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLAC#NASDAQ">KLAC</a>) as his final trade.
Adding support to his choice, Morgan Stanley analyst Shane Brett, on Monday, upgraded KLA from Equal-Weight to Overweight and raised the price target from $748 to $870.
Price Action:
<ul>
<li>Gilead Sciences gained 0.6% to close at $111.89 on Wednesday.</li>
<li>Amazon shares rose 2% to close at $196.01 during Wednesday's session.</li>
<li>KLA shares gained 0.6% to settle at $686.19 on Wednesday.</li>
<li>Alphabet shares slipped 0.01% to settle at $158.86 on Wednesday.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44604078/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-with-over-6-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks With Over 6% Dividend Yields</a></li>
</ul>
Photo: Shutterstock

AMZN

GILD

GOOG

GOOGL

KLAC

Amazon, Alphabet, KLA And A Health Care Stock On CNBC's 'Final Trades'

Legal

ORCL

PINS

SNAP

U.S. Vice President Vance Says TikTok Decision Will Come Before Deadeline

B of A Securities analyst Craig Siegenthaler maintains BlackRock (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLK#NYSE">BLK</a>) with a Buy and lowers the price target from $1196 to $1178.

B of A Securities Maintains Buy on BlackRock, Lowers Price Target to $1178

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the energy sector.
<h3 class="wp-block-heading">Kimbell Royalty Partners, LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRP#NYSE">KRP</a>)</h3>
<ul>
<li>Dividend Yield: 11.18%</li>
<li>Truist Securities analyst Neal Dingmann downgraded the stock from Buy to Hold and cut the price target from $22 to $16 on March 4, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Raymond James analyst John Freeman maintained a Strong Buy rating and raised the price target from $19 to $23 on Jan. 23, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: Kimbell Royalty Partners will release its first quarter financial results on Thursday, May 8, before the market open.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0403">KRP news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0403"><img loading="lazy" decoding="async" width="903" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045124/image-32.png" alt="" class="wp-image-854845" style="width:535px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045124/image-32.png 903w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045124/image-32-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045124/image-32-768x712.png 768w" sizes="(max-width: 903px) 100vw, 903px" /></a></figure>
<h3 class="wp-block-heading">Delek Logistics Partners, LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKL#NYSE">DKL</a>)</h3>
<ul>
<li>Dividend Yield: 10.13%</li>
<li>Raymond James analyst Justin Jenkins maintained an Outperform rating and raised the price target from $44 to $46 on Jan. 28, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Truist Securities analyst Neal Dingmann maintained a Buy rating and boosted the price target from $46 to $50 on Nov. 18, 2024. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: On Feb. 25, Delek Logistics Partners posted better-than-expected quarterly earnings.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest DKL <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0403">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0403"><img loading="lazy" decoding="async" width="903" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045153/image-1-8.png" alt="" class="wp-image-854846" style="width:652px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045153/image-1-8.png 903w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045153/image-1-8-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045153/image-1-8-768x720.png 768w" sizes="(max-width: 903px) 100vw, 903px" /></a></figure>
<h3 class="wp-block-heading">Western Midstream Partners, LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WES#NYSE">WES</a>)</h3>
<ul>
<li>Dividend Yield: 8.41%</li>
<li>UBS analyst Shneur Gershuni maintained a Neutral rating and lowered the price target from $40 to $37 on Nov. 15, 2024. This analyst has an accuracy rate of 82%.</li>
<li>Morgan Stanley analyst Robert Kad downgraded the stock from Equal-Weight to Underweight and cut the price target from $42 to $40 on Oct. 25, 2024. This analyst has an accuracy rate of 78%.</li>
<li>Recent News: On Feb. 26, Western Midstream posted weak quarterly earnings.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0403">latest WES news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0403"><img loading="lazy" decoding="async" width="910" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045227/image-33.png" alt="" class="wp-image-854849" style="width:435px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045227/image-33.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045227/image-33-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045227/image-33-768x709.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44622367/acuity-rh-and-3-stocks-to-watch-heading-into-thursday">Acuity, RH And 3 Stocks To Watch Heading Into Thursday</a> </li>
</ul>
Photo via Shutterstock

Dividends

Pre-Market Outlook

Wall Street's Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 8% Dividend Yields

Jefferies analyst Sean Milligan maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Underperform and lowers the price target from $54 to $44.

ENPH

Jefferies Maintains Underperform on Enphase Energy, Lowers Price Target to $44

B of A Securities analyst Craig Siegenthaler maintains Franklin Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) with a Underperform and lowers the price target from $20 to $17.

B of A Securities Maintains Underperform on Franklin Resources, Lowers Price Target to $17

As trade tensions heat up, one sector might have the immunity investors need &#8211; biopharma. JPMorgan analyst Chris Schott sees the industry as a relative &#8220;safe haven&#8221; despite looming <a href="https://www.benzinga.com/topic/tariffs">pharmaceutical-specific tariffs</a>, thanks to its high-margin business model and operational flexibility.
Read Also: <a href="https://www.benzinga.com/markets/equities/25/04/44620686/sp-500-nasdaq-futures-plunge-over-3-as-trumps-reciprocal-tariff-plan-hits-market-confidence">Trump&#8217;s &#8216;Reciprocal Tariff&#8217; Plan Hits Market Confidence As Dow Futures Drops Over 830 Points</a>
<h2 class="wp-block-heading">Tariffs Loom, But Biopharma Stands Strong</h2>
While the White House has not revealed details on pharma-related tariffs, broader trade restrictions announced today have put investors on edge. Schott acknowledges that some uncertainty will linger until the Section 232 pharmaceutical-specific tariffs are fully outlined in the coming weeks. However, he believes the sector has the tools to weather any potential impact.
Biopharma companies benefit from low capital expenditure intensity and high gross margins, making them more resilient in adjusting to cost pressures. Many also can shift intellectual property and manufacturing to the U.S. if needed while finding cost efficiencies elsewhere.
<h2 class="wp-block-heading">When Will The Impact Be Felt?</h2>
For now, companies appear to have time on their side. Schott anticipates that any direct financial impact from tariffs will likely hit in 2026 rather than 2025, as firms work through existing inventory already in the U.S. That gives the sector a buffer period to assess the extent of the tariffs and adapt accordingly.
<h2 class="wp-block-heading">Actionable ETFs For Investors</h2>
Investors looking to capitalize on biopharma&#8217;s defensive positioning amid tariff uncertainty may consider iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>) and SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>). These funds provide exposure to leading drugmakers who are expected to navigate potential trade disruptions more smoothly than other industries.
<h2 class="wp-block-heading">Key Questions Still Remain</h2>
Several unknowns still need to be addressed: What will the tariff levels be by country? Will they target low-cost active pharmaceutical ingredients (APIs) or final drug products with higher cost implications? Will these tariffs remain in place in the long term?
Schott expects companies to shed more light on these issues in their upcoming earnings calls. 
Until then, while tariffs shake the broader market, biopharma appears to have taken its medicine &#8211; staying strong while others scramble.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44622346/trumps-reciprocal-tariff-math-a-masterclass-in-economic-absurdity">Trump&#8217;s &#8216;Reciprocal Tariff&#8217; Math: A Masterclass In Economic Absurdity</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Health Care

General

iShares Dow Jones US Pharmaceuticals Index Fund

Biopharma: A 'Safe Haven' As Tariff Turmoil Rages On?

U.S. stock futures were lower this morning, with the Dow futures falling more than 1,000 points on Thursday.
Shares of RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) fell sharply in today's pre-market trading after the company reported weaker-than-<a href="https://in.benzinga.com/news/earnings/25/04/44616824/rh-q4-earnings-shares-sink-as-revenue-eps-miss-expectations">expected fourth-quarter financial results.</a>
RH reported fourth-quarter revenue of $812.41 million, missing the consensus estimate of $829.56 million, according to Benzinga Pro. The luxury retailer reported fourth-quarter adjusted earnings of $1.58 per share, missing analyst estimates of $1.92 per share.
RH shares dipped 26.6% to $182.97 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>AdvanSix Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASIX#NYSE">ASIX</a>) dipped 29% to $16.00 in pre-market trading.</li>
<li>Hamilton Beach Brands Holding Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBB#NYSE">HBB</a>) fell 24.7% to $15.01 in pre-market trading.</li>
<li>Waton Financial Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTF#NASDAQ">WTF</a>) shares dipped 20.3% to $5.60 in pre-market trading following a 65% decline on Wednesday. Waton Financial announced the closing of initial public offering with simultaneous full exercise of the over-allotment option.</li>
<li>RxSight, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) shares fell 19.2% to $21.00 in pre-market trading after the company announced preliminary first quarter revenue and revised 2025 guidance.</li>
<li>Franklin Covey Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) shares tumbled 14.4% to $23.87 in pre-market trading following weak quarterly sales.</li>
<li>lululemon athletica inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) fell 13% to $246.00 in pre-market trading.</li>
<li>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) fell 12.6% to $19.57 in pre-market trading.</li>
<li>NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) dipped 11.6% to $57.44 in pre-market trading.</li>
<li>Thryv Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) dipped 10.1% to $11.79 in pre-market trading.</li>
<li>BrightView Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) dipped 8.3% to $12.23 in pre-market trading.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) fell 7.4% to $207.25 in pre-market trading. Tigress Financial analyst Ivan Feinseth maintained Apple with a Strong Buy and raised the price target from $295 to $300.</li>
<li>CNB Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCNE#NASDAQ">CCNE</a>) fell 6.8% to $20.97 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell 5.7% to $266.66 in pre-market trading after gaining over 5% on Wednesday.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) dipped 5.3% to $104.56 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44622367/acuity-rh-and-3-stocks-to-watch-heading-into-thursday">Acuity, RH And 3 Stocks To Watch Heading Into Thursday</a></li>
</ul>
Photo via Shutterstock

Movers

AAPL

ASIX

CCNE

LULU

NVDA

RXST

THRY

TSLA

RH Posts Downbeat Earnings, Joins Apple, Tesla, Nvidia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

B of A Securities analyst Craig Siegenthaler maintains Affiliated Managers Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMG#NYSE">AMG</a>) with a Neutral and lowers the price target from $211 to $195.

B of A Securities Maintains Neutral on Affiliated Managers Group, Lowers Price Target to $195

Canaccord Genuity analyst Michael Graham maintains Sportradar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) with a Buy and raises the price target from $30 to $32.

SRAD

Canaccord Genuity Maintains Buy on Sportradar Gr, Raises Price Target to $32

B of A Securities analyst Craig Siegenthaler downgrades AllianceBernstein Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AB#NYSE">AB</a>) from Buy to Neutral and lowers the price target from $42 to $38.

Downgrades

B of A Securities Downgrades AllianceBernstein Holding to Neutral, Lowers Price Target to $38

Canaccord Genuity analyst Michael Walkley maintains BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) with a Hold and lowers the price target from $4.75 to $4.25.

Canaccord Genuity Maintains Hold on BlackBerry, Lowers Price Target to $4.25

B of A Securities analyst Craig Siegenthaler upgrades Janus Henderson Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>) from Neutral to Buy and lowers the price target from $57 to $43.

Upgrades

Janus Henderson Group plc Ordinary Shares

B of A Securities Upgrades Janus Henderson Group to Buy, Lowers Price Target to $43

Macro Economic Events

Econ #s

Economics

U.S Vice President Vance Says: Musk Will Continue To Be An Adviser -Fox Interview

Baird analyst Andrew Wittmann maintains UniFirst (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) with a Neutral and lowers the price target from $218 to $197.

Baird Maintains Neutral on UniFirst, Lowers Price Target to $197

Fort Lauderdale, FL, April 03, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=V-0nYzFaL2nHiXE8MQvul89eQUpKHI9mbKvadvKCrHeI2_s5h3R-RL4gPhAxDulc0wsznXaWrBuUjiN3QO0nDT6_i9uEokQLL5Vm6VDJIkA=">MARA Holdings, Inc.</a> (NASDAQ: <a href="https://www.globenewswire.com/Tracker?data=hgFvAausj0i1ZfS9Vgw1tw_AYTQ5E6eBzO7be50lW9S1iouX4Mod6HQjZluQpJyctURoTeOcW39mQ0ZH1oR07A==">MARA</a>) ("MARA" or the "Company"), a global leader in leveraging digital asset compute to support energy transformation, today published unaudited bitcoin ("bitcoin" or "BTC") production updates for March 2025.
Management Commentary "In March, our production saw a 17% month-over-month increase in blocks won, even as global hashrate and mining difficulty grew," said Fred Thiel, MARA's chairman and CEO. "Our bitcoin holdings surpassed 47,000 BTC during March and the 242 blocks mined were the third most in a month on record.
"MARAPool is the only self-owned and operated mining pool among public miners, offering distinctive control and efficiency. Operating our own pool means no fees to external operators, higher earnings and superior performance. MARA Pool's luck factor has exceeded the network average by over 10% since launch, meaning more blocks mined and higher rewards.
"Energized hashrate grew 1% over February and we expect to finish construction of our 40-megawatt data center in Ohio by the end of April. We will continue to focus on being the dominant player in bitcoin mining while expanding our footprint in energy generation."

MARA

MARA Announces Bitcoin Production And Mining Operation Updates For March 2025; Company Won 242 Blocks, A 17% Increase MoM. Increased Bitcoin Holdings To 47,531 BTC

Baird analyst Andrew Wittmann maintains Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) with a Neutral and lowers the price target from $46 to $43.

Baird Maintains Neutral on Fluor, Lowers Price Target to $43

NRXP

NRX Pharmaceuticals' HOPE Therapeutics Signs Term Sheet With A Global Medical Device Manufacturer; The Term Sheet Contemplates An Investment Of $2.5M To Purchase Series A Convertible Preferred Stock At $50M Pre-Money Valuation

Earnings

Press Releases

PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance

Deborah Kilpatrick Joins Sonder Capital as its Newest Venture Partner

PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock

PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock

PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024

Short Sellers

Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on PROCEPT BioRobotics (NASDAQ: PRCT)

PROCEPT BioRobotics® to Report Fourth Quarter 2024 Financial Results on February 25, 2025 and Attend the TD Cowen 45th Annual Healthcare Conference and the 2025 Leerink Partners Healthcare Conference

Comments

PROCEPT BioRobotics

Notizie

Ultime notizie per PROCEPT BioRobotics (NASDAQ:PRCT) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO